Invesco STOXX Europe 600 Optimised Health Care UCITS ETF Acc

Country exposure

as of 18 Sep 2020 (%)

Sector exposure

as of 18 Sep 2020 (%)

Top 10 Exposures as of 18 Sep 2020 (%)

Name ISIN Weight
ROCHE HOLDING PAR CH0012032048 10.12%
NOVARTIS N ORD CH0012005267 9.88%
SANOFI ORD FR0000120578 9.64%
ASTRAZENECA ORD GB0009895292 8.57%
NOVO NORDISK ORD DK0060534915 7.41%
BAYER N ORD DE000BAY0017 5.56%
GLAXOSMITHKLINE ORD GB0009252882 5.45%
LONZA GROUP ORD CH0013841017 3.90%
PHILIPS KON ORD NL0000009538 3.55%
ESSILORLUXOTTICA ORD FR0000121667 3.21%

Key information

Bloomberg ticker XDPS GY
ISIN IE00B5MJYY16
Benchmark BBG ticker SXODR
Management fee 0.30%
Swap fee 0.00%
NAV (25 Sep 2020) €299.17
AUM €27,575,615
Base currency EUR
Umbrella AUM (25 Sep 2020) €18,508,603,268

Key risks

Counterparty risk:  Other financial institutions provide services such as safekeeping of assets or as a counterparty to financial contracts such as derivatives. The Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.

Risk of using derivatives:  in order to reach its investment objective, the Fund enters into swap agreements which provide the performance of the Reference Index, and may imply a range of risks which could lead to an adjustment or even the early termination of the swap agreement.

Liquidity on secondary market risk:  Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily. On-exchange liquidity may be limited due to Reference Index suspension, a decision by one of the relevant stock exchanges, or a breach by the market maker of respective stock exchange requirements and guidelines. 

 

The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.

The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.

ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.